Nuffield Department of Primary Care Health Sciences (J.H.-B., A.T., A.R.B., A.B., R.B., F.D.R.H., S.A.J., P.A.), University of Oxford, United Kingdom.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, United Kingdom (J.L.O.).
Circ Cardiovasc Qual Outcomes. 2023 Apr;16(4):e009348. doi: 10.1161/CIRCOUTCOMES.122.009348. Epub 2023 Mar 28.
Behavioral weight management programs (BWMPs) enhance weight loss in the short term, but longer term cardiometabolic effects are uncertain as weight is commonly regained. We assessed the impact of weight regain after BWMPs on cardiovascular risk factors, diabetes, and cardiovascular disease.
Trial registries, 11 databases, and forward-citation searching (latest search, December 19) were used to identify articles published in English, from any geographical region. Randomized trials of BWMPs in adults with overweight/obesity reporting cardiometabolic outcomes at ≥12 months at and after program end were included. Differences between more intensive interventions and comparator groups were synthesized using mixed-effects, meta-regression, and time-to-event models to assess the impact of weight regain on cardiovascular disease incidence and risk.
One hundred twenty-four trials reporting on ≥1 cardiometabolic outcomes with a median follow-up of 28 (range, 11-360) months after program end were included. Median baseline participant body mass index was 33 kg/m; median age was 51 years. Eight and 15 study arms (7889 and 4202 participants, respectively) examined the incidence of cardiovascular disease and type 2 diabetes, respectively, with imprecise evidence of a lower incidence for at least 5 years. Weight regain in BWMPs relative to comparators reduced these differences. One and 5 years after program end, total cholesterol/HDL (high-density lipoprotein) ratio was 1.5 points lower at both times (82 studies; 19 003 participants), systolic blood pressure was 1.5 mm mercury and 0.4 mm lower (84 studies; 30 836 participants), and HbA1c (%) 0.38 lower at both times (94 studies; 28 083 participants). Of the included studies, 22% were judged at high risk of bias; removing these did not meaningfully change results.
Despite weight regain, BWMPs reduce cardiometabolic risk factors with effects lasting at least 5 years after program end and dwindling with weight regain. Evidence that they reduce the incidence of cardiovascular disease or diabetes is less certain. Few studies followed participants for ≥5 years.
URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42018105744.
行为体重管理项目(BWMP)在短期内可促进体重减轻,但由于体重通常会反弹,长期的心血管代谢效果尚不确定。我们评估了 BWMP 后体重反弹对心血管风险因素、糖尿病和心血管疾病的影响。
试验注册处、11 个数据库和向前引用搜索(最新搜索日期为 19 年 12 月)用于确定在任何地理区域发表的关于超重/肥胖成年人 BWMP 并报告计划结束后至少 12 个月时和之后的心血管代谢结果的英文文章。使用混合效应、元回归和时间到事件模型综合比较强化干预和对照组之间的差异,以评估体重反弹对心血管疾病发病率和风险的影响。
纳入了 124 项报告至少 1 项心血管代谢结果的试验,中位随访时间为计划结束后 28 个月(范围为 11-360 个月)。参与者基线时的平均体重指数为 33kg/m2,平均年龄为 51 岁。8 个和 15 个研究组(分别为 7889 名和 4202 名参与者)分别检查了心血管疾病和 2 型糖尿病的发病率,至少 5 年内的证据不明确。BWMP 相对于对照组的体重反弹减少了这些差异。计划结束后 1 年和 5 年,总胆固醇/高密度脂蛋白(HDL)比值均降低了 1.5 点(82 项研究,19003 名参与者),收缩压降低了 1.5mmHg 和 0.4mmHg(84 项研究,30836 名参与者),HbA1c(%)降低了 0.38 点(94 项研究,28083 名参与者)。纳入的研究中,有 22%的研究被认为存在高偏倚风险;去除这些研究并没有显著改变结果。
尽管存在体重反弹,BWMP 仍可降低心血管代谢风险因素,且效果至少可在计划结束后持续 5 年,而随着体重反弹,效果逐渐减弱。证据表明,BWMP 可降低心血管疾病或糖尿病的发病率,但并不确定。很少有研究随访参与者超过 5 年。
网址:https://www.crd.york.ac.uk/PROSPERO/;唯一标识符:CRD42018105744。